A synthetic hexapeptide that mimics SNAP-25 to inhibit SNARE complex formation, reducing neurotransmitter release and facial muscle contractions for anti-wrinkle effects.
Hoppel. Magdalena M; Reznicek. Gottfried G; Kählig. Hanspeter H; Kotisch. Harald H; Resch. G&#x...
Researchers tested how different cream types affect how well the anti‑aging peptide acetyl‑hexapeptide‑8 (AH‑8) gets into skin. They found that a special “water‑in‑oil‑in‑water” (W/O/W) multiple‑emulsion cream lets a lot more of the peptide penetrate the skin than regular oil‑in‑water or water‑in‑oil creams.
Researchers built a tiny 3‑D skin model that includes nerve cells and showed that a peptide called acetyl‑hexapeptide‑3 (often sold as Argireline) can get through the outer skin layer, gather around the nerves, and trigger several skin‑health benefits.
Wisniewski. Joy D JD; Ellis. Dana L DL; Lupo. Mary P MP
The article says a skin cream containing acetyl‑hexapeptide‑3 can smooth wrinkles and works well together with Botox shots, possibly letting you use fewer injections. It also notes that using antioxidant and anti‑inflammatory skin products before or after peels, lasers, or other cosmetic procedures can speed healing and cut down on redness or dark spots.
Kraeling. Margaret E K ME; Zhou. Wanlong W; Wang. Perry P; Ogunsola. Oluwatosin A OA
When a cream with acetyl‑hexapeptide‑8 (a popular anti‑wrinkle peptide) is applied to skin, almost all of it washes off, and only a tiny fraction stays in the outermost skin layer. It barely reaches deeper layers and never makes it into the bloodstream, suggesting it’s safe but also that it probably won’t work beyond the surface.
Palmieri. B B; Noviello. A A; Corazzari. V V; Garelli. A A; Vadala. M M
A small, informal study of 26 people with skin scars or wrinkles used a cream that contains 10% acetyl‑hexapeptide‑8 (Argireline). After applying the cream and massaging the area for a few minutes, participants showed better skin hydration, elasticity, and overall appearance, with no reported allergies.
Wu. Yun Y; Cao. Kun K; Zhang. Wei W; Zhang. Guangxian G; Zhou. Maojun M
Researchers tested five skin‑care peptides, including acetyl‑hexapeptide‑3, in human skin cells. They found that a blend of four peptides (carnosine, acetyl tetrapeptide‑5, hexapeptide‑11, and acetyl‑hexapeptide‑3) lowered oxidative damage and boosted collagen‑like and elastin proteins, suggesting the mix could help protect skin from aging.
The study found that using tiny solid microneedle patches on skin makes it easier for small protein-like molecules, including acetyl‑hexapeptide‑3, to pass through the skin. The effect was stronger for smaller peptides and seemed linked to the flow of water through the skin.
Lim. Seng Han SH; Tiew. Wen Jun WJ; Zhang. Junying J; Ho. Paul Chi-Lui PC; Kachouie. Nezamoddin N NN...
Scientists figured out the best shape for tiny needle patches that can push the anti‑wrinkle peptide acetyl‑hexapeptide‑3 through the skin. By using 3‑D printing they made patches with needles that are 800 µm long, 100 µm at the tip, spaced 800 µm apart, and 400 µm at the base, and these worked well on both flat and curved patches. Lab tests showed these patches let more of the peptide get into the skin, which could make wrinkle treatments more effective.
Lim. Seng Han SH; Kathuria. Himanshu H; Amir. Muhd Hafiz Bin MHB; Zhang. Xiyuan X; Duong. Hien T T H...
Scientists created a custom‑made microneedle patch using a special 3D‑printed polymer that can safely carry the anti‑wrinkle peptide acetyl‑hexapeptide‑3 through the skin, overcoming its usual poor absorption.
Lim. Seng Han SH; Sun. Yuanyuan Y; Thiruvallur Madanagopal. Thulasi T; Rosa. Vinicius V; Kang. Lifen...
Researchers tweaked the anti‑wrinkle peptide Argireline (called Arg0) to make it soak through skin better. Two new versions, Arg2 and Arg3, got through human skin more easily in lab tests, and Arg3 also showed the strongest ability to block a wrinkle‑related signal in nerve‑like cells. The work suggests that specially modified Argireline could work better in creams, but it’s still early‑stage lab data.
Wang. Yuan Y; Wang. Mei M; Xiao. Shengxiang S; Pan. Ping P; Li. Ping P; Huo. Jia J
A short 4‑week study showed that applying the peptide argireline twice a day to the skin around the eyes reduced wrinkle depth in Chinese volunteers, with almost half the treated group seeing visible improvement while the placebo group saw none.
Krishnan. Gayathri G; Roberts. Michael S MS; Grice. Jeffrey J; Anissimov. Yuri G YG; Moghimi. Hamid...
The study shows that using a mild electric current (iontophoresis) can boost the amount of peptide that passes through the skin—up to 30‑times more than just applying it normally. How well it works depends on things like the peptide’s size and charge, the skin’s pH, how much peptide you put on, and the salt levels in the solution. For the popular anti‑wrinkle peptide Argireline (acetyl‑hexapeptide‑3), the right conditions (neutral‑to‑slightly basic pH, low extra salt, and the correct current direction) can make skin delivery much more effective.
Wang. Yuan Y; Wang. Mei M; Xiao. Xiang Sheng XS; Huo. Jia J; Zhang. Wei Ding WD
Argireline (acetyl‑hexapeptide‑3) applied to the skin of aged mice twice a day for six weeks improved the skin’s microscopic structure: more sturdy type I collagen and less type III collagen, which together suggest a tighter, younger‑looking skin. The study supports the idea that this peptide can help reduce wrinkles, echoing earlier human trials that reported safety and wrinkle‑reduction benefits.
McGuinn. Kathleen P KP; Ross. Nicholas A NA; Wang. Jordan V JV; Saedi. Nazanin N
A small pilot study (10 people) found that using a skin serum containing a tripeptide and acetyl‑hexapeptide‑3 together with a 1540 nm non‑ablative fractional laser made stretch marks look better, caused less post‑laser dark spots, and made patients happier with the results.
Kluczyk. Alicja A; Ludwiczak. Julita J; Modzel. Maciej M; Kuczer. Mariola M; Cebrat. Marek M; Bierna...
The study shows that Argireline, a peptide marketed as a needle‑free Botox, is actually present in many face creams, but it can get oxidized (especially the methionine part) which may affect how well it works. The researchers developed a lab method to detect both the intact peptide and its oxidized form, and they point out that other ingredients in the cream can influence this oxidation.
Grosicki. Marek M; Latacz. Gniewomir G; Szopa. Annamaria A; Cukier. Anna A; Kieć-Kononowicz. K...
The study looked at how toxic the anti‑wrinkle peptide Argireline (acetyl‑hexapeptide‑3) is to different human cells. It found that Argireline does reduce cell growth, but only at concentrations that are dozens to thousands of times higher than the amounts used in skin creams, making it appear quite safe for typical topical use.
A small study with 24 healthy volunteers showed that a skin cream containing acetyl‑hexapeptide‑3 (a peptide often called Argireline) reduced wrinkle‑related skin measurements and improved the skin’s water barrier. The related peptide tripeptide‑10‑citrulline also showed anti‑wrinkle effects, and the two together might work better, though the exact benefit of the combo wasn’t clear.
Lupin. Mark M; Bjerring. Peter P; Andriessen. Anneke A; Chantrey. Jonquille J; Fabi. Sabrina Guillen...
A small group of doctors tried a skin cream that contains a peptide called acetyl‑hexapeptide‑8 (along with other ingredients) together with Botox injections. They reported that the combo made skin look brighter and reduced fine lines and wrinkles more than Botox alone.
Edison. Brenda L BL; Parsa. Ramine R; Dufort. Marisa M; Tierney. Neena K NK; Green. Barbara A BA; Fa...
There is continuous demand for safe, effective cosmetic ingredients to treat the signs of aging skin, including fine lines, wrinkles, brown spots, discoloration, laxity, and sagging. While there are a plethora of cosmeceutical peptides, few combine anti-aging and anti-inflammatory benefits with small size.
Preclinical and clinical studies evaluated the anti-inflammatory properties, anti-aging benefits, and tolerability of acetyl dipeptide-31 amide (AP31), a novel, small, anti-aging micropeptide, to understand its impact as a multifaceted, cosmetic, anti-aging, and anti-inflammaging ingredient.
In vitro, AP31 statistically significantly reduced the release of inflammatory mediators interleukin (IL)-4, IL-6, IL-8, IL-17, and tumor necrosis factor alpha, and statistically significantly increased levels of dermal extracellular matrix components, ie, procollagen, elastin, decorin, fibronectin, and hyaluronic acid (all P<0.05 vs vehicle controls). Statistically significant increases in extracellular matrix biomarker levels were also seen in AP31-treated human skin explants (8 days). In human skin equivalents, AP31 favorably influenced cellular pathways known to contribute to skin aging. AP31 positively impacted genes involved in barrier function, skin hydration, skin plumping, and epidermal metabolism. Clinical evaluations of a finished product over 16 weeks demonstrated improvements in jawline sagging, global lift, nasolabial fold appearance, fine lines and wrinkles, smoothness, skin tone, and hyperpigmentation. Subject self-assessment of efficacy was consistent with the clinical grading. No statistically significant changes from baseline in tolerability assessments of edema, erythema, dryness, burning, stinging, itching, or tightness were reported.
AP31 is a novel, multifunctional, non-irritating, cosmeceutical micropeptide that improves clinical signs of aging, lifts and contours facial skin, and reduces inflammation markers. J Drugs Dermatol. 2025;24(1):23-33. doi:10.36849/JDD.8786.
Lungu. C C; Considine. E E; Zahir. S S; Ponsati. B B; Arrastia. S S; Hallett. M M
Injectable botulinum neurotoxin (BoNT) is the principal effective treatment for blepharospasm (BSP). This trial explores the safety and efficacy of topical acetyl hexapeptide-8 (AH8), a competitive SNAP25 inhibitor, as a potential new therapy in BSP.
Double-blind, placebo-controlled, randomized trial of daily topical application of AH8 in 24 patients with BSP. The primary outcome was time to return to baseline Jankovic Blepharospasm Rating Scale (JBRS) after a BoNT injection simultaneously with the initiation of AH8. Patients displaying a strictly regular pattern of response to 3-monthly injections of BoNT were included.
There were no significant adverse events. There was a trend for longer time until return to baseline JBRS after injection in the active group compared to placebo (3.7 months vs. 3.0 months), and for better scores in the active group. One-third (4/12) of the patients in the active group had a considerable extension of symptom control after BoNT (range: 3.3-7.1 months).
Topical AH8 is safe and promising for extending the duration of action of BoNT therapy for BSP.